MicroRNA-211 Modulation for Refractory Epilepsy Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy are unsatisfactorily effective for a third of cases, and there is a need for new therapeutic approaches that target the underlying mechanisms of seizures, particularly focusing on microRNA-211, which is implicated in neuronal function and seizure susceptibility.
Innovation Solution
Modulating the expression levels of microRNA-211 in the brain, specifically using a doxycycline-suppressible system in mice to demonstrate its role in regulating neuronal hyper-synchronization and cholinergic synaptic receptor pathways, thereby influencing seizure susceptibility and related phenotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for epilepsy, then most patients receive some benefit, but one third of cases remain unsatisfactorily controlled
Solution Approach 1:
The patent changes the molecular parameter by modulating microRNA-211 expression levels in the brain. By using doxycycline-suppressible expression systems, the invention achieves precise control over miR-211 concentrations, thereby altering neuronal excitability and seizure susceptibility parameters to treat refractory epilepsy cases that do not respond to conventional treatments
2Reliability
If microRNA-211 levels are reduced in the brain, then seizure susceptibility increases, but this could potentially cause harmful effects
Solution Approach 1:
The patent implements a feedback-controlled expression system using doxycycline as an inducible regulator. The doxycycline-suppressible expression system allows real-time modulation of miR-211 levels based on observed seizure activity, enabling the system to maintain optimal miR-211 concentrations that prevent seizures while avoiding excessive suppression that could cause harmful effects
Solution Approach 2:
The invention transitions from static treatment to dynamic control by using an inducible expression system. The miR-211 expression can be dynamically adjusted through doxycycline administration, allowing the therapeutic effect to adapt to changing neurological conditions and seizure patterns, thereby optimizing seizure threshold control while minimizing harmful effects
Data Source
AI summary
Method for controlling for the appearance of seizures in the mammalian brain comprising modifying the abundance of a specific miRNA—miR-211, for uses in preventing seizures and providing a model system to examine the effect of a drug or a treatment to seizures.